Glenmark secures China approval for Ryaltris

The approval granted with zero supplementation requests is an important milestone in Glenmark’s respiratory pipeline

RedHill secures final $10.5M court judgment for enforcement

RedHill has obtained a court-approved asset attachment in South Korea to prevent Kukbo from transferring or disposing of assets ahead of enforcement of the judgment

GSK signs $745 million licensing agreement with Empirico for novel respiratory siRNA therapy

The deal reinforces GSK’s leadership in respiratory care and builds upon the company’s expanding COPD portfolio

Dr. Reddy’s launches novel molecule ‘Tegoprazan’ in India

Tegoprazan, a novel patented molecule indicated for acid-related gastrointestinal diseases, is launched in India under the brand name PCAB

GC Biopharma submits IND to begin Phase 3 clinical trial for Barycela in Thailand

WHO, ITU, and WIPO release new report on AI use in traditional medicine

The global TCIM market is expected to reach nearly US$ 600 billion by 2025

Ichnos Glenmark Innovation announces global commercialization strategy for ISB 2001

IGI partners with AbbVie and grants exclusive rights to globally develop, manufacture, and commercialize ISB 2001 across North America, Europe, Japan, and Greater China

Mezzion secures $20 million funding to advance Phase 3 clinical development of Udenafil for fontan patients

LG Chem sets sights on global market with launch of diabetes combination therapy Zemidapa

Launched in Thailand, the ASEAN hub, marking an early entry into the fast-growing combination therapy market (DPP-4 and SGLT-2 inhibitor combination) with strong potential for market leadership

Sun Pharma introduces Fexuclue in India for treatment of Erosive Esophagitis

Fexuprazan has the longest half-life of 9 hours among potassium-competitive acid blockers